NicOx selects NCX 6560 for cardiovascular development

By Elaine Rigoli

Tampa, Fla., Sept. 6 - NicOx SA said Wednesday that it plans to move NCX 6560 into development as a new statin with the potential for broadened and increased benefit in cardiovascular disease.

NicOx said preclinical results show that NCX 6560 has numerous positive effects in validated models of the most common cardiovascular disorders, which go beyond those seen with leading marketed statins.

The Sophia Antipolis, France-based biopharmaceutical company said advancement of NCX 6560 into preclinical development is a clear demonstration of the company's determination to advance its research and development in the cardiometabolic area, one of its core therapeutic franchises.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.